دورية أكاديمية
Phenotypic changes in low-density lipoprotein particles as markers of adverse clinical outcomes in COVID-19.
العنوان: | Phenotypic changes in low-density lipoprotein particles as markers of adverse clinical outcomes in COVID-19. |
---|---|
المؤلفون: | Carmo HRP; Cardiology Division, Unicamp Medical School, SP, Brazil., Yoshinaga MY; Department of Biochemistry, Institute of Chemistry, University of São Paulo, SP, Brazil. Electronic address: marcosyukio@gmail.com., Castillo AR; Cardiology Division, Unicamp Medical School, SP, Brazil., Britto Chaves-Filho A; Department of Biochemistry, Institute of Chemistry, University of São Paulo, SP, Brazil., Bonilha I; Cardiology Division, Unicamp Medical School, SP, Brazil., Barreto J; Cardiology Division, Unicamp Medical School, SP, Brazil., Muraro SP; Laboratory of Emerging Viruses, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, SP, Brazil., de Souza GF; Laboratory of Emerging Viruses, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, SP, Brazil., Davanzo GG; Laboratory of Immunometabolism, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, SP, Brazil., Perroud MW Jr; Pneumology Division, Unicamp, SP, Brazil., Lukhna K; Division of Cardiology, University of Cape Town, Cape Town, South Africa., Ntsekhe M; Division of Cardiology, University of Cape Town, Cape Town, South Africa., Davidson S; Hatter Cardiovascular Institute, University College London, London, UK., Velloso LA; Internal Medicine Department, Unicamp Medical School, SP, Brazil., Nadruz W; Cardiology Division, Unicamp Medical School, SP, Brazil., Carvalho LSF; Cardiology Division, Unicamp Medical School, SP, Brazil., Sáinz-Jaspeado M; Mercodia AB, Uppsala, Sweden., Farias AS; Laboratory of Neuroimmunomodulation, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, SP, Brazil; Hub of Global Health (HGH), University of Campinas, Campinas, SP, Brazil., Proença-Módena JL; Laboratory of Emerging Viruses, Department of Genetics, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, SP, Brazil; Hub of Global Health (HGH), University of Campinas, Campinas, SP, Brazil., Moraes-Vieira PM; Laboratory of Immunometabolism, Department of Genetics, Evolution, Microbiology and Immunology, Institute of Biology, University of Campinas, Campinas, SP, Brazil; Hub of Global Health (HGH), University of Campinas, Campinas, SP, Brazil., Karathanasis SK; Lipoprotein Metabolism Laboratory Translational Vascular Medicine Branch National Heart, Lung and Blood Institute National Institutes of Health, Bethesda, MD, USA., Yellon D; Hatter Cardiovascular Institute, University College London, London, UK., Miyamoto S; Department of Biochemistry, Institute of Chemistry, University of São Paulo, SP, Brazil., Remaley AT; Lipoprotein Metabolism Laboratory Translational Vascular Medicine Branch National Heart, Lung and Blood Institute National Institutes of Health, Bethesda, MD, USA., Sposito AC; Cardiology Division, Unicamp Medical School, SP, Brazil. Electronic address: sposito@unicamp.com. |
المصدر: | Molecular genetics and metabolism [Mol Genet Metab] 2023 Apr; Vol. 138 (4), pp. 107552. Date of Electronic Publication: 2023 Feb 27. |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Academic Press Country of Publication: United States NLM ID: 9805456 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-7206 (Electronic) Linking ISSN: 10967192 NLM ISO Abbreviation: Mol Genet Metab Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Orlando, FL : Academic Press, c1998- |
مواضيع طبية MeSH: | 1-Alkyl-2-acetylglycerophosphocholine Esterase* , COVID-19*, Humans ; Lipoproteins, LDL ; Biomarkers ; Lysophosphatidylcholines |
مستخلص: | Background and Aims: Low-density lipoprotein (LDL) plasma concentration decline is a biomarker for acute inflammatory diseases, including coronavirus disease-2019 (COVID-19). Phenotypic changes in LDL during COVID-19 may be equally related to adverse clinical outcomes. Methods: Individuals hospitalized due to COVID-19 (n = 40) were enrolled. Blood samples were collected on days 0, 2, 4, 6, and 30 (D0, D2, D4, D6, and D30). Oxidized LDL (ox-LDL), and lipoprotein-associated phospholipase A2 (Lp-PLA2) activity were measured. In a consecutive series of cases (n = 13), LDL was isolated by gradient ultracentrifugation from D0 and D6 and was quantified by lipidomic analysis. Association between clinical outcomes and LDL phenotypic changes was investigated. Results: In the first 30 days, 42.5% of participants died due to Covid-19. The serum ox-LDL increased from D0 to D6 (p < 0.005) and decreased at D30. Moreover, individuals who had an ox-LDL increase from D0 to D6 to over the 90th percentile died. The plasma Lp-PLA2 activity also increased progressively from D0 to D30 (p < 0.005), and the change from D0 to D6 in Lp-PLA2 and ox-LDL were positively correlated (r = 0.65, p < 0.0001). An exploratory untargeted lipidomic analysis uncovered 308 individual lipids in isolated LDL particles. Paired-test analysis from D0 and D6 revealed higher concentrations of 32 lipid species during disease progression, mainly represented by lysophosphatidyl choline and phosphatidylinositol. In addition, 69 lipid species were exclusively modulated in the LDL particles from non-survivors as compared to survivors. Conclusions: Phenotypic changes in LDL particles are associated with disease progression and adverse clinical outcomes in COVID-19 patients and could serve as a potential prognostic biomarker. Competing Interests: Declaration of Competing Interest Dr. Miguel Sáinz-Jaspeado works at Mercodia company (Mercodia AB, Uppsala, Sweden) as product Manager & Medical Science Liaison and, kindly provided the enzyme-linked immunoassay (ELISA) kits for oxidized low-density lipoprotein measures. (Copyright © 2023. Published by Elsevier Inc.) |
References: | J Lipid Res. 2021;62:100129. (PMID: 34599996) J Biol Chem. 2009 Dec 4;284(49):33833-40. (PMID: 19815546) Am J Respir Cell Mol Biol. 2016 May;54(5):624-35. (PMID: 26859434) Cardiovasc Drugs Ther. 2022 Oct;36(5):925-930. (PMID: 34169381) Nutrition. 2018 Nov;55-56:7-14. (PMID: 29960160) Rev Assoc Med Bras (1992). 2021 Feb;67(2):224-229. (PMID: 34406246) J Lipid Res. 2008 May;49(5):1137-46. (PMID: 18281723) Curr Med Chem. 2007;14(30):3209-20. (PMID: 18220755) Semin Perinatol. 2022 Feb;46(1):151540. (PMID: 34872750) Front Public Health. 2021 Aug 18;9:705916. (PMID: 34490188) Clin Nutr ESPEN. 2021 Oct;45:91-101. (PMID: 34620375) Curr Protoc Bioinformatics. 2016 Sep 07;55:14.10.1-14.10.91. (PMID: 27603023) Clin Exp Immunol. 1999 May;116(2):326-31. (PMID: 10337026) Isr Med Assoc J. 2015 Jun;17(6):370-3. (PMID: 26233997) Am J Cardiol. 2015 Mar 1;115(5):557-62. (PMID: 25727079) JAMA. 2020 Apr 28;323(16):1582-1589. (PMID: 32219428) Lipids Health Dis. 2011 Sep 28;10:170. (PMID: 21955667) Viruses. 2019 Jan 16;11(1):. (PMID: 30654597) Clin Proteomics. 2019 Jul 16;16:29. (PMID: 31341447) Life Sci. 2020 Apr 15;247:117443. (PMID: 32084434) Trends Microbiol. 2007 Jul;15(7):301-9. (PMID: 17566739) J Nutr Biochem. 2021 Nov;97:108809. (PMID: 34192591) Trends Mol Med. 2020 Dec;26(12):1086-1100. (PMID: 32861590) FASEB J. 2020 Aug;34(8):9843-9853. (PMID: 32588493) Crit Care Med. 2015 Jun;43(6):1255-64. (PMID: 25738856) Cell Metab. 2020 Sep 1;32(3):498-499. (PMID: 32877692) PLoS Pathog. 2022 Apr 21;18(4):e1010443. (PMID: 35446921) J Lipid Res. 2004 Jul;45(7):1169-96. (PMID: 15102878) Digestion. 2013;87(4):223-8. (PMID: 23751273) Biophys J. 2001 Jul;81(1):243-54. (PMID: 11423410) Atherosclerosis. 2010 Jan;208(1):10-8. (PMID: 19570538) Cardiovasc Drugs Ther. 2022 Nov 29;:. (PMID: 36445625) Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1536-42. (PMID: 10845869) Respir Med. 2021 Oct;187:106605. (PMID: 34507024) Am J Med Genet C Semin Med Genet. 2021 Sep;187(3):301-311. (PMID: 33474836) Antioxidants (Basel). 2021 Feb 07;10(2):. (PMID: 33562403) SAGE Open Med. 2021 Feb 01;9:2050312121991246. (PMID: 33614035) Food Sci Nutr. 2020 Oct 27;8(11):6144-6152. (PMID: 33282265) Circ Res. 2011 Jan 21;108(2):235-48. (PMID: 21252151) Cell Syst. 2021 Jan 20;12(1):23-40.e7. (PMID: 33096026) Nature. 2020 Mar;579(7798):265-269. (PMID: 32015508) |
فهرسة مساهمة: | Keywords: COVID-19; Lipoprotein-associated phospholipase A2; Oxidized low-density lipoprotein; Quantitative lipidomics |
المشرفين على المادة: | EC 3.1.1.47 (1-Alkyl-2-acetylglycerophosphocholine Esterase) 0 (Lipoproteins, LDL) 0 (Biomarkers) 0 (Lysophosphatidylcholines) |
تواريخ الأحداث: | Date Created: 20230308 Date Completed: 20230425 Latest Revision: 20230509 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC9969752 |
DOI: | 10.1016/j.ymgme.2023.107552 |
PMID: | 36889041 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1096-7206 |
---|---|
DOI: | 10.1016/j.ymgme.2023.107552 |